Amplia Therapeutics (ASX: ATX) has announced the completion of the second cohort of its Phase 1b/2a ACCENT clinical trial, which will be testing the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of its AMP945 drug.

Amplia Therapeutics says the testing will combine the drug with gemcitabine and nab-paclitaxel chemotherapy in frontline patients with pancreatic cancer.

It also says the primary endpoint of the trial is the Objective Response Rate (ORR) of patients to treatment.

Amplia Therapeutics says after 1 month of treatment, the trial’s Safety Committee will review the clinical data collected and, subject to the data, authorise dose escalation of AMP945 in a subsequent cohort.